Conjugate vaccines are formed by coupling the key antigen (like bacteria polysaccharide, tumor antigen) with a carrier protein such as toxoid and virus-like particle (VLP). The former one is taken as the weak antigen and the later one isstrong antigen to elicite a stronger immunological response to the weak antigen.
Yaohai Bio-Pharma has more than a decade of microbial CDMO experience. Based on the GMP workshop with Biosafety Level 1 (BSL-1) and Biosafety Level 2 (BSL-2), we provide a one-stop solution for microbial strain development, fermentation, extraction, purification of microbial-produced antigens and carrier proteins, as well as chemically coupling, aseptic filling of conjugate vaccine.
According to the customized needs of customers, we provide customers with intermediates, vaccine drug substance (DS, API) or drug produce (DP) that meet quality standards, as well as GMP production records and test reports.
Haemophilus B (Hib), consisting Hib polysacchride and a carrier protein, is the most commonly used conjugate vaccine. Other conjugate vaccines were also approved against bacteria pathogens like Streptococcus pneumoniae and Neisseria meningitidis.
Diphtheria toxoid (DT), diphtheria CRM197, tetanus toxoid (TT), meningococcal outer membrane protein complex (OMPC) are widely used carrier proteins in approved conjugate vaccines.
Besides, other conjugate vaccines as prophylactic or therapeutic biologics are being researched in pre-clinical and clinical trials.
Table 1. List of Approved Conjugate Vaccines
Brand Name |
Generic Name |
Carrier Protein |
Company |
Liquid PedvaxHIB |
Haemophilus B Conjugate Vaccine |
Meningococcal outer membrane protein complex (OMPC) |
Merck, Merck Sharp & Dohme (MSD) |
ActHIB |
Haemophilus B Conjugate Vaccine |
Tetanus Toxoid (TT) |
Sanofi |
Hiberix |
Haemophilus B Conjugate Vaccine |
Tetanus Toxoid (TT) |
GlaxoSmithKline (GSK) |
Menveo |
Meningococcal (Groups A, C, Y, and W-135) Oligosaccharide Conjugate Vaccine |
Diphtheria CRM197 |
GlaxoSmithKline (GSK) |
Menactra |
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Conjugate Vaccine |
Diphtheria Toxoid (DT) |
Sanofi |
MenQuadfi |
Meningococcal (Groups A, C, Y, W) Conjugate Vaccine |
Tetanus Toxoid (TT) |
Sanofi |
Prevnar 13 |
Pneumococcal 13-valent Conjugate Vaccine |
Diphtheria CRM197 |
Pfizer, Wyeth |
Vaxneuvance |
Pneumococcal 15-valent Conjugate Vaccine |
Recombinant CRM197 |
Merck, Merck Sharp & Dohme (MSD) |
Prevnar 20 |
Pneumococcal 20-valent Conjugate Vaccine |
Diphtheria CRM197 |
Pfizer, Wyeth |
Cimavax-EGF |
Epidermal growth factor (EGF) cancer vaccine |
Meningococcal P64k Protein |
CIMAB |
Related Service: Carrier Protein (Recombinant) or Carrier Protein (Extracted) |
Grade |
Deliverables |
Specification |
Applications |
GMP, BSL-1/BSL-2 |
Intermediate substance |
Microbial-produced antigen |
Investigational new drug (IND), Clinical trial authorisation (CTA), Clinical trial supply, Biologic license application (BLA), Commercial supply |
Microbial-produced carrier protein |
|||
Drug substance |
Conjugate vaccine |
||
Drug product |
Vials (liquid) |
||
Vials (lyophilized) |
|||
Other Dosage Forms |